RCS - IXICO plc - Life Molecular Imaging – Neuraceq Supply Agreement

IXICOAnnouncement

15/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240415:nRSO5269Ka&default-theme=true

RNS Number : 5269K  IXICO plc  15 April 2024

 

15 April 2024

 

IXICO plc

("IXICO" or the "Company")

 

Life Molecular Imaging - Neuraceq® Master Supply Agreement

 

IXICO plc (AIM: IXI), the medical imaging advanced analytics company
delivering intelligent insights in neuroscience, today provides information on
its agreement with Life Molecular Imaging (LMI) for the supply of LMI's
Neuraceq® Amyloid PET tracer (Florbetaben-18F) for use in pharma-sponsored
clinical trials. Neuraceq® is a diagnostic agent that improves early
detection and characterization of chronic and life-threatening diseases such
as Alzheimer's, leading to better therapeutic outcomes and improved quality of
life.

As a result of its agreement with LMI, IXICO is able to further extend its
service offering to providing Neuraceq® PET tracer supply to complement
IXICO's well-established PET imaging services and image data analytics.
LMI's provision of tracer supply to imaging centres together with IXICO's
oversight of imaging will minimise the operational burden to trial sponsors
and will improve patient experience, ultimately driving study eligibility and
efficacy endpoint delivery.

 

Andrew Stephens, Chief Medical Officer of Life Molecular Imaging, commented:

''We are pleased to be partnering with IXICO to further strengthen access to
Neuraceq® to clinical trials. We hope that our partnership will offer
Sponsors an additional streamlined route to tracer supply.''

 

Giulio Cerroni, Chief Executive Officer of IXICO, commented:

''IXICO is committed to the continuous development of our suite of AI enabled
analytics and reader services for innovative new PET tracers and so we are
delighted to be partnering with LMI to improve access and supply to LMI's
Neuraceq. We anticipate that the extension of this Neuraceq tracer
co-ordination service from IXICO will be very well received by our global
biopharmaceutical Sponsors."

 

For further information please contact:

 

 IXICO plc
 Giulio Cerroni, Chief Executive Officer  +44 (0)20 3763 7499

 Grant Nash, Chief Financial Officer

This is an RNS Reach announcement and the information contained is not
considered to have a significant impact on management's expectations of the
Group's performance. RNS Reach is an investor communication service aimed at
assisting listed and unlisted (including AIM quoted) companies to distribute
non-regulatory news releases into the public domain. Information required to
be notified under the AIM Rules for Companies, Market Abuse Regulation or
other regulation would be disseminated as an RNS regulatory announcement and
not on RNS Reach.

 

About IXICO | Advanced Analytics | Intelligent Insights.

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

 

More information is available on www.IXICO.com (http://www.IXICO.com)

 

 

About Life Molecular Imaging (LMI)

Life Molecular Imaging (LMI) is an international pharma company dedicated to
developing and offering novel cutting-edge PET radiopharmaceuticals for
imaging of neurodegenerative and cardiovascular diseases. The organization
strives to be a leader in the molecular imaging field. Our mission is to
pioneer innovative PET products that improve early detection and
characterization of chronic and life-threatening diseases, leading to better
therapeutic outcomes and improved quality of life. By advancing novel PET
radiopharmaceuticals for molecular imaging, LMI is focusing on a key field of
modern medicine. LMI is an affiliate of Life Healthcare Group - an
international people-centred, diversified healthcare organization with four
decades of experience in the South African private healthcare sector.

More information about Life Molecular Imaging (LMI) at https://life-mi.com
(https://life-mi.com)

About Life Healthcare Group https://www.lifehealthcare.co.za/
(https://www.lifehealthcare.co.za/)

About Neuraceq® (florbetaben 18F) https://neuraceq.com/
(https://neuraceq.com/)

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAELDFLFLEFA